Sixten Borg
1 – 10 of 30
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- Individual perspectives on outcomes in Diabetes
- New Diabetes Questionnaire to add patients' perspectives to diabetes care for adults with type 1 and type 2 diabetes : nationwide cross-sectional study of construct validity assessing associations with generic health-related quality of life and clinical variables
- 2019
-
Quality of life in chronic conditions using patient-reported measures and biomarkers : a DEA analysis in type 1 diabetes
Borg, Sixten LU ; Gerdtham, Ulf-G LU
; Eeg-Olofsson, Katarina
; Palaszewski, Bo
and Gudbjörnsdottir, Soffia
(2019)
In Health Economics Review
9(1).
p.1-17
Mark
- Health-related quality of life and glycaemic control among adults with type 1 and type 2 diabetes - A nationwide cross-sectional study
- Can people afford to pay for health care? : New evidence on financial protection in Sweden
-
Patient-reported outcome and experience measures for diabetes : development of scale models, differences between patient groups and relationships with cardiovascular and diabetes complication risk factors, in a combined registry and survey study in Sweden
Borg, Sixten LU ; Eeg-Olofsson, Katarina ; Palaszewski, Bo ; Svedbo Engström, Maria ; Gerdtham, Ulf-G LU
and Gudbjörnsdottir, Soffia
(2019)
In BMJ Open
9(1).
Mark
- 2018
- A disease-specific questionnaire for measuring patient-reported outcomes and experiences in the Swedish National Diabetes Register : Development and evaluation of content validity, face validity, and test-retest reliability
- 2017
- Prediction models for exacerbations in different COPD patient populations : Comparing results of five large data sources
- 2016
- Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
- Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease : Are Current Models Suitable to Evaluate Personalized Medicine?